A neuroendocrine tumour (NET) is a rare tumour with an estimated incidence of 5.25 per 100 000 in adults ([@bib38]; [@bib22]). The exact incidence of NETs in children is not known, but a small study reported an incidence of 1.14 per one million children ([@bib31]). In children, little research has been performed on NETs with only small case-series of 2 to 36 patients reported ([@bib21]).

Neuroendocrine tumours in children seem to differ from NETs in adults. In adults, the most common locations of NETs are the lungs and the gastrointestinal tract, specifically the rectum and small intestine ([@bib38]). In children, NETs are most commonly found in the appendix (87.5% [@bib12]), whereas in adults the incidence of NETs in the appendix is relatively low (3% of all NETs; [@bib38]). Appendiceal NETs in children are indolent tumours which rarely metastasise and have an excellent overall survival close to 100% ([@bib21]). Survival in adults depends on the localisation of the NET and disease stage at diagnosis ([@bib38]). The 5-year survival rate of localised appendiceal NETs is 88% ([@bib38]), which is less than the estimated survival in children.

Genetic predisposition may have a role in the development of NETs. These tumours have been reported as part of various hereditary cancer syndromes as shown in [Table 1](#tbl1){ref-type="table"}, and familial occurrence of NETs has also been reported in the absence of these syndromes ([@bib18]). In addition, adults diagnosed with a NET have an increased risk of developing second primary malignancies ([@bib4]). These characteristics are suggestive for hitherto unrecognised genetic predisposing factors involved in the development of NETs in adults.

On the basis of the findings in adult studies, we suspect genetic tumour predisposition syndromes might have a role in the aetiology of NETs in children as well. To support this hypothesis we studied the occurrence of second primary malignancies and the presence of additional features or diagnoses in children with a NET.

Here we describe a large study of NETs in 483 children in the Netherlands using PALGA, the nationwide pathology database. The first aim of this study was to provide an overview of patient and tumour characteristics in children with a NET. The collected data also enabled us to study the adherence to surgical guidelines in children with appendiceal NETs. Second, we aimed to find evidence to support our hypothesis that genetic tumour predisposition is a contributing factor in the aetiology of NETs. To our knowledge, this is the largest case-series described in the literature so far.

Materials and methods
=====================

We retrospectively collected our data from PALGA, the nationwide network and registry of histopathology and cytopathology ([@bib10]) which encompasses all pathology reports from all hospitals in the Netherlands since 1991. To obtain data from all children in the Netherlands with a NET, we performed a search with the search terms 'carcinoid\' OR 'neuroendocrine tumour\' with limitations to the ages 0--18. This search resulted in data from 505 children who were diagnosed with a NET between 1991 and 2013. In the [@bib7] and in our national guidelines no diagnostic requirements for the diagnosis of a NET are defined. Diagnosis was based on HE staining in unequivocal cases and additional immunohistochemical staining if deemed necessary by the pathologist, as is in daily practice. Data were processed de-identified and contained 1105 excerpts in total. Information about age at diagnosis, gender, localisation of the tumour, tumour size, presence of metastasis, surgical treatment and presence of additional features or diagnoses was extracted. The file also included the data about other conditions for which a pathologist was consulted that occurred prior to or in follow-up of the NET. Many reports included the data on the medical history of the child, which could shed light on conditions for which examination by a pathologist was not necessary.

A total of 22 patients were excluded from the final analysis; six because data were incomplete and 16 due to another diagnosis. Patients in the latter group did not have a NET, but a different tumour with neuroendocrine characteristics or a different type of tumour with a NET only in the initial differential diagnosis.

Patient characteristics were compared using crosstabs in conjunction with a standard Pearson chi-square test. Statistical significance was considered to exist if two-sided *P*-values were below 0.01. The incidence of NETs was calculated by dividing the number of children with a NET by the total Dutch childhood population for each of the years between 2009 to 2013 (available at [statline.cbs.nl](http://statline.cbs.nl)). The average incidence is based on these 5 years. Statistical analysis was carried out using the SPSS statistical package ([@bib19]). Both the privacy committee and the scientific committee of PALGA approved the study design. Because of the strict anonymity, no additional ethical approval was required.

Results
=======

Patient and tumour characteristics
----------------------------------

A total of 483 patients (174 males and 309 females) were included in the analysis. The mean follow-up of patients was 143 months (median 146 months, range 2--275 months). From 1991 to 2013 on average 21 children (range 14--26) were diagnosed with a NET per year in the Netherlands, which averages an incidence rate of 5.40 per million children per year. The median age of patients at the time of diagnosis was 15 years (range 1--18 years) and NETs were more frequently seen in girls. We found a male : female ratio of 1 : 1.78. We observed no difference in age at diagnosis by sex or by primary tumour localisation. Details regarding age at diagnosis and the distribution of tumour localisation are presented in [Table 2](#tbl2){ref-type="table"}.

Appendiceal NETs were observed most frequently (441 patients, 91.3%), followed by bronchopulmonary tumours (25 patients, 5.2%). Two patients presented with a NET localised in another (benign) tumour: a NET in a mature cystic teratoma and a NET in a mature sacrococcygeal teratoma. In one patient with liver metastasis of a NET, the primary tumour could not be identified. The localisations of the primary tumours in the patients varied significantly by sex, with increased incidence of appendiceal NETs in females (95.1% *vs* 84.5%, *P*\<0.001) and increased incidence of bronchopulmonary NETs in male patients (10.3% *vs* 2.3%, *P*\<0.001). The distribution of gender related to tumour location is shown in [Table 3](#tbl3){ref-type="table"}.

### Metastatic disease

At the time of diagnosis, the majority of patients did not have metastatic disease (*N*=467, 96.7%). In 13 patients (2.7%) locoregional lymph node metastasis was present. In three patients (0.6%), distant metastasis to the liver was found. Of these patients one had a primary NET in the stomach and the second a NET in a mature cystic teratoma. In the third patient with distant metastasis the primary tumour was not identified after an extensive search including multiple stomach biopsies and an appendectomy. Appendiceal NETs metastasise significantly less than NETs in other locations (*P*\<0.001). Extended patient and tumour characteristics of patients with metastatic disease are described in [Supplementary Table 1](#sup1){ref-type="supplementary-material"}.

### Appendiceal tumours

We found the appendix to be the most common location of a NET in children (*n*=441, 91.3%). Histopathological data of the appendiceal NETs are presented in [Table 4](#tbl4){ref-type="table"}. Four patients had multiple NETs in the appendix, with a maximum of four NETs in one appendix ([Table 5](#tbl5){ref-type="table"}). All but two patients presented with clinical symptoms of an acute abdomen, suggestive of appendicitis. In the remaining two patients, the appendiceal NETs were incidentally found during surgery for another indication: a patient with Crohn\'s disease underwent an ileocecal resection and a patient with Familial adenomatous polyposis (FAP) underwent a proctocolectomy. In 403 patients, an appendectomy was performed without additional surgery. In 33 patients an additional hemicolectomy or ileocecal resection was performed.

Genetic predisposition
----------------------

Genetic tumour predisposition can be suspected when a child has multiple primary tumours, multiple NETs or specific additional features or diagnoses that could indicate genetic predisposition. A total of 18 patients in our cohort matched these criteria ([Table 5](#tbl5){ref-type="table"}). In six patients (1.2%) a second primary malignancy was found. Two of these patients had Von Hippel--Lindau disease (VHL) and one was clinically diagnosed with Multiple Endocrine Neoplasia syndrome type 1 (MEN-1), although from the PALGA report we learned that a causative mutation had not yet been identified. Three patients with an appendiceal NET (0.6%) had additional premalignant lesions. One patient had multiple adenomatous polyps of low to intermediate grade dysplasia in the colon and in this patient the tumour predisposition syndrome FAP was diagnosed. The other patient had CIN2 moderate dysplasia of the cervix at a remarkably young age of 17 years. The third patient had a dysplastic naevus, also at a very young age of 10 years.

Five patients (1.0%) presented with multiple NETs in the same organ. Four had multiple appendiceal NETs and one patient had multiple pancreatic NETs. This latter patient also had a MEN-1 diagnosis. Four other patients had additional features or diagnoses that have been described in tumour predisposition syndromes before, that is pilomatrixomas, multiple angiolipomas and an osteoma. We found a high incidence of Crohn\'s disease or strongly suspected inflammatory bowel disease in 9 patients (1.9%, 2 confirmed, 7 patients suspected). An overview of all additional diagnoses found in our cohort is available in [Supplementary Table 2](#sup1){ref-type="supplementary-material"}.

Discussion
==========

To our knowledge, this is the largest case-series of NETs in children described in literature and we were able to confirm previously reported characteristics of these tumours. In addition, our results suggest that genetic tumour predisposition has an important role in the aetiology of NETs in children, as we found proven and strongly suspected genetic tumour predisposition syndromes in 18 children.

The incidence of 5.40 per one million children per year in the Netherlands is higher than the estimated incidence of 1.14 per million children ([@bib31]). The incidence we report is probably more realistic since we conducted a nationwide study. In line with previous studies, we found that the appendix is by far the most common site for NETs in children ([@bib29]). Tumour localisation varied significantly between sexes with females developing significantly more appendiceal NETs then males. This may be explained by the increased lifetime risk for a female to undergo an appendectomy (23.1% *vs* 12.0% for males; [@bib2]) with consequently more incidental findings of appendiceal NETs. It is unknown whether this explanation is also applicable to the childhood population. Compared with females, males develop more bronchopulmonary NETs. Strikingly, in adult studies, females develop more bronchopulmonary NETs ([@bib27]; [@bib38]). We do not have an explanation for the predilection of bronchopulmonary NETs in males in our cohort. However, the number of pulmonary tumours we found is relatively small and this finding needs confirmation.

A NET in children is reported to have a relatively indolent disease course ([@bib35]; [@bib21]). Data about survival are lacking in our study due to the study design, however only a few patients developed locoregional lymph node metastases (*N*=13) or distant metastases (*N*=3). NETs in the stomach, colon, lungs and NETs localised in different tumours seem to metastasise more often (50, 20, 16 and 50%, respectively). Because these localisations are rare in children these percentages are based on small numbers and therefore the strength of this observation may be questionable. However, stricter surveillance in children with these tumour localisations seems warranted.

Exact guidelines for the surgical treatment of appendiceal NETs in children are not available. In adult patients, a right-sided hemicolectomy or an ileocecal resection is advised when histopathological risk factors are present, according to the ENETS consensus treatment guidelines for neuroendocrine tumours of the appendix ([@bib30]). The ENETS consensus guidelines state that additional surgery is indicated when one of the following criteria is present: tumour size \>2 cm, invasion of the mesoappendix, localisation of the tumour at the base of the appendix or an incomplete initial resection of the tumour ([@bib30]). On the basis of these criteria additional surgery was indicated in 89 patients with appendiceal NETs, but performed in only 27 of these patients. Six patients had additional surgery, although there was no strict indication according to these guidelines. It is noteworthy that these treatment guidelines were not available in the early nineties, so they are not applicable for our entire cohort. No clear difference was seen between the group of patients in whom additional surgery was performed, compared with the group of patients in whom additional surgery was not performed. On the other hand, six patients did have additional surgery despite the fact that it was not indicated based on the tumour characteristics. The role of additional surgery in the management of patients with appendiceal NETs is controversial, particularly in children and adolescents, as NETs in these patients tend to behave less aggressively ([@bib34]). Indeed, none of the 62 patients who did not undergo additional surgery developed histological proven metastatic disease during follow-up. Perhaps clinicians consider these guidelines to extreme for these tumours in children and therefore they opt for a less invasive treatment. The development of a guideline for surgical treatment in children with appendiceal NETs may help find more consensus on this subject.

We found a significant number of patients (*N*=18, 3.7% [Table 5](#tbl5){ref-type="table"}) in whom a genetic tumour predisposition syndrome was diagnosed or strongly suspected. Genetic predisposition can be suspected based on several factors, like for instance the presence of multiple primary tumours in a patient ([@bib28]) and cancer in combination with specific features that fit one of the known tumour predisposition syndromes, such as specific skin lesions (e.g., café-au-lait macules in neurofibromatosis) or congenital anomalies ([@bib25]). Finally, a family history of cancer could be indicative of genetic predisposition. Unfortunately, data about family history were unavailable in our study.

A total of six patients developed a second primary malignancy (SPM) during the period of observation (1.2%). None of these malignancies was treatment related since none of these children received chemotherapy or radiotherapy. Therefore, these children had an indication for genetic counselling and genetic testing ([@bib28]). In three of these children, we indeed found evidence for a known cancer predisposing syndrome ([Table 5](#tbl5){ref-type="table"}). The two tumour predisposition syndromes VHL and MEN-1 occurred in a much higher incidence in our cohort than in the general population (1 : 242 *vs* 1 : 36 000 ([@bib24]) and 1 : 242 *vs* 1 : 50 000 ([@bib8]), respectively; *P*\<0.001 for both comparisons). All of these patients had pancreatic NETs, which suggests pancreatic NETs in particular are highly associated with tumour predisposition syndromes. We could not confirm that a genetic predisposition syndrome was present in the other three children with multiple malignancies, which does not necessarily mean that such a diagnosis has not been made. In particular, genetic tumour predisposition is likely to have a role in the patient with an adenoid cystic breast carcinoma at age 17, since this is a tumour that is very unusual in childhood. Mean age at diagnosis of this tumour is 63 years ([@bib13]) and to our knowledge, no case reports of this tumour in children have been described.

In studies on SPMs in adult patients with gastrointestinal NETs, the incidence of SPMs ranges from 12--46% ([@bib16]). In children, only one retrospective study was performed and no SPMs were identified ([@bib12]). However, this study was rather small and contained a cohort of only 32 patients with a short median follow-up of 84 months. Even though our follow-up was relatively short in many of the patients (median of 143 months, range 2--275) we identified 6 patients with a SPM. If follow-up would be extended, it is possible that more SPMs at relatively young age will be identified.

We have identified one child with FAP and several children with Crohn\'s disease in our cohort. Neuroendocrine tumours in FAP and Crohn\'s disease have been described before ([@bib20]; [@bib37]; [@bib32]). We found an incidence of Crohn\'s disease or strongly suspected inflammatory bowel disease of 0.4--1.9% (400--1900 per 100 000) which is significantly higher than the incidence of Crohn\'s disease in the general paediatric population (6.6 per 100 000; *P*\<0.001; [@bib1]). The most important explanation for the association between Crohn\'s disease and NETs is probably the higher number of colectomies performed in children with these conditions, which can result in the incidental finding of a NET ([@bib11]). The hypothesis that inflammation causes hyperstimulation of endocrine cells leading to hyperplasia and neoplasia remains to be proven ([@bib37]). A third explanation might be that genetic predisposing factors for FAP and Crohn also predispose for developing NETs.

The other remarkable findings shown in [Table 5](#tbl5){ref-type="table"} are features that are not previously reported in patients with NETs, but some are associated with tumour predisposition syndromes in which NETs have been described. For example, pilomatrixomas and osteomas have been described in FAP ([@bib5]; [@bib36]). Since these are all rare findings in children, the combination with childhood cancer may suggest the presence of a genetic predisposition syndrome. Possibly even more patients have interesting additional diagnoses, but using PALGA as our main source of information we missed the patients with additional diagnoses of which no biopsy was taken or tissue removed.

Conclusion
==========

We identified several patients with a confirmed or suspected tumour predisposition syndrome and showed that paediatric pancreatic NETs in particular are associated with tumour predisposition syndromes, since 4 out of 5 patients with a pancreatic NET had such a syndrome. The presence of a pancreatic NET in a child should therefore warrant genetic counselling, genetic testing and surveillance advises in line with the results of genetic testing. Studies including exome- or genome-wide genetic testing are needed to further identify the role of genetic predisposition in the aetiology of NETs.

In addition, we found that the current treatment guidelines need revision and improved implementation in light of the much better prognosis of appendiceal NETs in children compared with adults.
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###### 

Click here for additional data file.

###### NETs in hereditary tumour predisposition syndromes

  **Tumour predisposition syndrome**   **Type of NETs**                                                                  **Other features**                                                                             **Reference**
  ------------------------------------ --------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------- ----------------------
  MEN-1                                Duodeno-pancreatic (54--61%) Bronchial (3.1--3.2%) Thymic (2.6--6% in men only)   Primary hyperparathyroidism Pituitary tumours Adrenal tumours                                  ([@bib14]; [@bib15])
  VHL                                  Pancreatic (12.3--17%), mostly non-functioning                                    Renal cell carcinoma Pheochromocytoma Hemangioblastoma Pancreatic lesions (cystic and solid)   ([@bib6]; [@bib17])
  NF1                                  Somatostatinoma Insulinoma Duodenal (\<1%)                                        Café-au-lait macules Neurofibromas Optic glioma Iris hamartomas                                ([@bib3]; [@bib23])
  Tuberous sclerosis                   Pancreatic (\<1%)                                                                 Hamartomatous lesions in brain, skin, eyes, heart, lungs and kidneys                           ([@bib3]; [@bib23])
  Lynch syndrome                       Small intestine Appendix                                                          Colorectal adenocarcinomas Endometrial-, stomach- and urinary tract tumours                    ([@bib26]; [@bib33])
  FAP                                  Gastrointestinal tract                                                            Adenomatous polyps Colorectal carcinoma Extraintestinal tumours                                ([@bib9]; [@bib20])

Abbreviations: FAP=familial adenomatous polyposis; MEN-1=multiple endocrine neoplasia type 1; NET=neuroendocrine tumour; NF1=neurofibromatosis type 1; VHL=Von Hippel--Lindau syndrome.

###### Age and disease stage at diagnosis of NETs by gender and primary tumour site

                                                     **Age at diagnosis in years**    **Disease stage;** ***N*** **(%)**                          
  ------------------------------------- ------------ ------------------------------- ------------------------------------ ------------ ---------- -----------
  **Gender**                                                                                                                                      
  Male                                  174 (36.0)   15.0                                           6--18                 165 (94.8)   8 (4.6)    1 (0.6)
  Female                                309 (64.0)   15.0                                           1--18                 302 (97.7)   5 (1.6)    2 (0.6)
  **Primary tumour site**                                                                                                                         
  Appendix                              441 (91.3)   14.4                                           4--18                 434 (98.4)   7 (1.6)    --
  Lung                                  25 (5.2)     14.9                                           10--18                21 (84.0)    4 (16.0)   --
  Colon                                 5 (1.0)      14.0                                           2--18                 4 (80.0)     1 (20.0)   --
  Pancreas[a](#t2-fn2){ref-type="fn"}   4 (0.8)      15.5                                           14--17                4 (100.0)    --         --
  Stomach                               4 (0.8)      17.5                                           16--18                2 (50.0)     1 (25.0)   1 (25.0)
  In other tumour                       2 (0.4)      9.5                                            1--18                 1 (50.0)     --         1 (50.0)
  Small intestine                       1 (0.2)      16.0                                             --                  1 (100.0)    --         --
  Unknown                               1 (0.2)      17.0                                             --                  --           --         1 (100.0)

Abbreviation: NET=neuroendocrine tumour.

In total, 5 patients had a pancreatic NET, but in one patient this pancreatic NET occurred years after the diagnosis of a stomach NET.

This table describes only the primary tumour site.

###### Distribution of gender related to localisation of the tumour

                             **Male**   **Female**               
  ------------------------- ---------- ------------ ----- ------ ---------
  **Primary tumour site**                                        
  Appendix                     147         84.5      294   95.1   \<0.001
  Lung                          18         10.3       7    2.3    \<0.001
  Colon                         3          1.7        2    0.6        
  Pancreas                      2          1.2        2    0.6        
  Stomach                       3          1.7        1    0.3        
  In other tumour               0          0.0        2    0.6        
  Small intestine               1          0.6        0    0.0        
  Unknown                       0          0.0        1    0.3        
  Total                        174         100       309   100        

*P*-values could not be calculated for the other tumour sites, since patient number were too small.

###### Histopathological data of NETs

                                           ***N***    **%**[a](#t4-fn1){ref-type="fn"}
  ---------------------------------------- --------- ----------------------------------
  **Appendiceal NETs (*n*=441)**                     
  **Localisation of tumour**                                          
   Base of the appendix                    19                       4.9
   Apex/mid-region of the appendix         366                      95.1
   Total[b](#t4-fn2){ref-type="fn"}        385                      100
  **Histology grade**                                                 
   Grade 1                                 152                      98.1
   Grade 2                                 3                        1.9
   Total                                   155                      100
  **Tumour size**                                                     
   \<10 mm                                 222                      61.5
   10--20 mm                               128                      35.5
   \>20 mm                                 11                       3.0
   Total                                   361                      100
  **Invasion of mesoappendix**                                        
   Yes                                     83                       22.6
   No                                      282                      76.6
   Questionable                            3                        0.8
   Total                                   368                      100
  **Complete resection?**                                             
   Yes                                     365                      94.8
   No                                      16                       4.2
   Questionable                            4                        1.0
   Total                                   385                      100
  **NETs outside the appendix (*n*=42)**             
  **Histology grade**                                                 
   Grade 1                                 30                       88.2
   Grade 2                                 4                        11.8
   Total                                   34                       100
  **Complete resection?**                                             
   Yes                                     25                       73.5
   No                                      6                        17.6
   Questionable                            3                        8.8
   Total                                   34                       100

Percentages are calculated based on the available data per tumour characteristic.

Differences in total numbers per subheading are due to missing data.

###### Patients with syndromes or features indicative of genetic cancer predisposition

  **No.**                                                                       **Gender**   **Primary NET, age in years**   **Additional features or diagnoses (age in years)**                                     **Tumour predisposition syndrome**   **Follow-up in months**
  ----------------------------------------------------------------------------- ------------ ------------------------------- --------------------------------------------------------------------------------------- ------------------------------------ -------------------------
  **Patients with multiple primary malignancies**                                                                                                                                                                                                         
  1                                                                             Male         Pancreas, 17                    Bilateral renal cell carcinoma (21)                                                     VHL confirmed                        163
  2                                                                             Male         Appendix, 14                    Myeloproliferative disease (23), probably chronic idiopathic myelofibrosis              No                                   158
  3                                                                             Male         Stomach, 18                     Multiple pancreatic NETs (29); no metastasis from stomach NET Parathyroid hyperplasia   Clinical MEN-1, mutation not found   146
  4                                                                             Male         Appendix, 14                    Anaplastic T-cell lymphoma (26), dysplastic nevus (29)                                  No                                   247
  5                                                                             Female       Pancreas, 16                    Cerebellar hemangioblastoma (22)                                                        VHL confirmed                        150
  6                                                                             Female       Appendix, 15                    Adenoid cystic carcinoma breast (17)                                                    No                                   261
  **Patients with premalignant lesions at a remarkably young age**                                                                                                                                                                                        
  7                                                                             Male         Appendix, 17                    Multiple adenomatous polyps of low to intermediate grade dysplasia                      FAP confirmed                        235
  8                                                                             Female       Appendix, 16                    CIN2 moderate dysplasia of the cervix (17)                                              No                                   49
  9                                                                             Female       Appendix, 17                    Dysplastic nevus (10)                                                                   No                                   143
  **Patients with multiple NETs**                                                                                                                                                                                                                         
  10                                                                            Male         Pancreas, 14                    Two pancreatic NETs and pancreatic microadenomatosis Parathyroid hyperplasia            MEN-1 confirmed                      57
  11                                                                            Female       Appendix, 17                    Two NETs in the appendix, 7 mm (top) and 8 mm (base)                                    No                                   100
  12                                                                            Male         Appendix, 17                    Two NETs in the appendix, 16 mm (top) and 4 mm (base)                                   No                                   223
  13                                                                            Female       Appendix, 17                    Two NETs in the appendix, 3 mm and 8mm                                                  No                                   53
  14                                                                            Female       Appendix, 13                    Four NETs in the appendix, sizes unknown                                                No                                   4
  **Patients with other features that could indicate genetic predisposition**                                                                                                                                                                             
  15                                                                            Female       Appendix, 18                    Osteoma of the ear                                                                      No                                   23
  16                                                                            Female       Appendix, 16                    Pilomatrixoma (18)                                                                      No                                   116
  17                                                                            Male         Lung, 12                        Pilomatrixoma (15)                                                                      No                                   130
  18                                                                            Male         Lung, 18                        Nine angiolipomas (22)                                                                  No                                   139

Abbreviations: CIN=cervical intra-epithelial neoplasia; FAP=familial adenomatous polyposis; MEN-1=multiple endocrine neoplasia syndrome type 1; NET=neuroendocrine tumour; VHL=Von Hippel--Lindau disease.
